Adage Capital Management
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5831878
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5782421
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5772526
SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred stock financing. Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants. New investors, including D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, joined the company's existing investors ...
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5765520
-
Adage Capital Boosts Stake in AnnTaylor (ANN) to 5.8%
-
Form SC 13G ANNTAYLOR STORES CORP Filed by: ADAGE CAPITAL PARTNERS GP LLC
-
Form SC 13G TESSERA TECHNOLOGIES Filed by: ADAGE CAPITAL PARTNERS GP LLC
-
Form SC 13G PACTIV CORP Filed by: ADAGE CAPITAL PARTNERS GP LLC
